

Original Research

# Physical Activity and Systemic Biomarkers in Persons With COPD: Insights from a Web-Based Pedometer-Mediated Intervention

Megan N. Berube, BS<sup>1\*</sup> Stephanie A. Robinson, PhD<sup>2,3\*</sup> Emily S. Wan, MD, MPH<sup>1,4,5,6</sup> Maria A. Mongiardo, MPH<sup>1</sup>  
Elizabeth B. Finer, MA<sup>1</sup> Marilyn L. Moy, MD, MSc<sup>1,4,6</sup>

## Abstract

**Background:** The relationships between physical activity (PA) and exercise performance and systemic biomarkers in persons with chronic obstructive pulmonary disease (COPD) have not been well characterized. The impact of PA promotion on biomarkers reflecting myocardial stress, systemic inflammation, and muscle injury is unclear.

**Methods:** This secondary analysis used 3 previously published studies in persons with COPD (2 examined a PA intervention that promoted community-based walking for 3 months) to explore these relationships. PA (daily step counts) and exercise performance (6-minute walk test [6MWT]) were assessed. Serum N-terminal pro- $\beta$ -type natriuretic peptide (NT-proBNP), the soluble receptor for advanced glycation end products (sRAGE), and muscle-type creatine kinase (CKMM) were assayed at baseline and 3 months. General linear models examined associations between PA/exercise performance and systemic biomarkers at baseline and the effect of the PA intervention on change in biomarkers.

**Results:** Participants included 366 U.S. Veterans: 98% male, mean age  $70\pm 8$  years, and forced expiratory volume in 1 second percentage predicted  $59\pm 21\%$ . Lower baseline NT-proBNP, but not sRAGE or CKMM, was associated with higher daily step count ( $-0.95\text{pg/ml}$  per 1000 steps/day,  $p=.060$ ) and higher 6MWT distance ( $-0.80\text{pg/ml}$  per 100 meters,  $p=.001$ ). Change in daily step count, but not 6MWT, was significantly greater in the intervention ( $789\pm 1864$ ) compared to the control group ( $-174\pm 1448$ ;  $p=.002$ ). The PA intervention had no significant impact on change in the systemic biomarkers.

**Interpretation:** Exercise performance is associated with NT-proBNP in persons with COPD. A 3-month community-based walking intervention is not associated with myocardial stress or muscle injury as assessed by NT-proBNP and CKMM, respectively.

Clinical Trial Registration: NCT01772082 and NCT02099799

1. Research and Development Service, VA Boston Healthcare System, Boston, Massachusetts, United States
2. Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Boston, Massachusetts, United States
3. The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, United States
4. Pulmonary and Critical Care Medicine Section, VA Boston Healthcare System, Boston, Massachusetts, United States
5. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States
6. Harvard Medical School, Boston, Massachusetts, United States

\* contributed equally to this work/co-first authors.

## Abbreviations:

**6MWT**=6-minute walk test; **AEs**=acute exacerbations; **BMI**=body mass index; **CAD**=coronary artery disease; **CHF**=congestive heart failure; **CI**=confidence interval; **CKMM**=muscle-type creatine kinase; **COPD**=chronic obstructive pulmonary disease; **ELISA**=enzyme-linked immunosorbent assay; **ESC**=Every Step Counts study; **FEV<sub>1</sub>%pred**=forced expiratory volume in 1 second percentage predicted; **GOLD**=Global initiative for chronic Obstructive Lung Disease; **IQR**=interquartile range; **NT-proBNP**=N-terminal pro- $\beta$ -type natriuretic peptide; **PA**=physical activity; **RAGE**=receptor for advanced

glycation end products; **RCTs**=randomized clinical trials; **SAMO**=improving exercise tolerance and health-related quality of life in Veterans with COPD study; **SD**=standard deviation; **SE**=standard error; **sRAGE**=soluble receptor for advanced glycation end products; **VA**=Veterans Affairs; **WEB**=Walking and Education to Breathe study

## Funding Support:

This work was supported in part by the Department of Veterans Affairs, Rehabilitation Research and Development Service (Career Development Award 2, F6847W [Moy]; CDA2 IK2RX002165 [Wan]; Merit O1150-R [Moy]) and Health Services and Research Development Service (Career Development Award 2, 21-187 [Robinson]).

## Citation:

Berube MN, Robinson SA, Wan ES, Mongiardo MA, Finer EB, Moy ML. Physical activity and systemic biomarkers in persons with COPD: insights from a web-based pedometer-mediated intervention. *Chronic Obstr Pulm Dis.* 2024;11(4):369-381. doi: <https://doi.org/10.15326/jcopdf.2023.0472>

## Publication Dates:

**Date of Acceptance:** April 24, 2024

**Published Online Date:** May 3, 2024

For personal use only. Permission required for all other uses.

**Address correspondence to:**

Stephanie A. Robinson, PhD  
 200 Springs Rd. Bldg 70  
 Bedford, MA 01730  
 Phone: (781) 687-4776  
 Email: Stephanie.Robinson5@va.gov

**Keywords:**

chronic obstructive pulmonary disease; exercise; pulmonary disease; walk test

**This article has an online supplement.****Introduction**

Chronic obstructive pulmonary disease (COPD) results in dyspnea and reductions in exercise performance.<sup>1</sup> COPD is also associated with a wide range of systemic derangements that involve, to varying degrees, cardiovascular effects, systemic inflammation, and skeletal muscle dysfunction.<sup>1-4</sup> Physical activity (PA) promotion is the standard of care and improves clinical outcomes for patients with COPD.<sup>1</sup> Independent of lung function, increased PA is associated with decreased risk of hospitalization, acute exacerbations (AEs), and mortality.<sup>5-10</sup> Currently, it is unclear whether community-based PA promotion impacts cardiac and skeletal muscle responses and whether changes in systemic inflammation mediate the observed benefits of PA promotion on morbidity and mortality in persons with COPD.

N-terminal pro- $\beta$ -type natriuretic peptide (NT-proBNP), the soluble receptor for advanced glycation end products (sRAGE), and muscle-type creatine kinase (CKMM) show promise as potential biomarkers of systemic response to exercise and PA promotion. In COPD, NT-proBNP is a cardiac hormone that independently predicts PA,<sup>11</sup> AEs,<sup>12</sup> and mortality.<sup>13</sup> A systemic biomarker for cardiac dysfunction, NT-proBNP levels increase as myocardial wall stress increases.<sup>14,15</sup> It is plausible that dynamic hyperinflation or increases in pulmonary arterial pressure during exercise in COPD would negatively impact cardiac function and increase NT-proBNP levels. Secondly, although exercise training or PA promotion have well-known benefits in COPD, an anti-inflammatory effect has not yet been established.<sup>16-22</sup> Most COPD studies have focused on only 1 or a limited number of markers of systemic inflammation and comparison between studies is limited by the heterogeneity of intensity, duration, frequency, and type of exercise studied.<sup>16-22</sup> The soluble form of the pattern recognition receptor for advanced glycation end products (RAGE) is found in serum. RAGE contributes to the pathogenesis of COPD by inducing inflammation and tissue injury, while sRAGE counteracts these effects by acting as a decoy receptor and preventing ligands from binding to RAGE.<sup>23</sup> Lower sRAGE levels are associated with greater cigarette smoking exposure and

more severe emphysema.<sup>24,25</sup> sRAGE has emerged as a functionally relevant marker of systemic inflammation across many clusters in COPD.<sup>26</sup> Finally, changes in serum levels of CKMM, an indirect biomarker of skeletal muscle damage, have been studied after short, local, exhaustive exercise training in the laboratory in persons without<sup>27</sup> and with COPD.<sup>28-31</sup> It is unknown whether CKMM changes with community-based walking over longer periods of PA promotion.

The relationships between PA and exercise performance and NT-proBNP, sRAGE, and CKMM in persons with COPD are unclear. In addition, systemic biomarker responses to community-based PA promotion have not been well characterized in COPD. The current literature focuses on changes in these biomarkers in the laboratory setting after bouts of high-intensity exercise rather than community-based walking which more accurately reflects patients' usual activities in their home environment. We have developed a web-based, pedometer-mediated PA intervention for persons with COPD<sup>32-35</sup> based on the Theory of Self-Regulation.<sup>36</sup> The intervention provides 4 key components to promote behavior change: individualized goal setting, iterative step-count feedback for self-monitoring, educational and motivational content for disease self-management, and social support in the form of an online community forum. In 3 randomized controlled trials in persons with COPD, the intervention has been shown to be efficacious in increasing PA as measured by daily step counts, compared to controls, over 3–6 months.<sup>32-35</sup> The PA intervention has been shown to be efficacious in improving daily step counts by 779, 804, and 1312 steps per day,<sup>33-35</sup> compared to controls. These improvements are both clinically and statistically significant based on published minimal clinically important differences for daily step count that range from 350 to 1100 steps per day<sup>37,38</sup> and their association with a decreased risk for AEs.<sup>39</sup>

In this secondary data analysis, we explored the baseline cross-sectional associations between PA and exercise performance with NT-proBNP, sRAGE, and CKMM. We hypothesized that higher NT-proBNP, CKMM, and sRAGE would be associated with greater PA/exercise. As a separate goal, we explored whether the magnitude of changes in daily step counts resulting from a 3-month PA intervention that promotes community-based walking would impact these biomarkers. We hypothesized that a 3-month walking intervention would not change NT-proBNP or CKMM, and may decrease systemic inflammation as reflected by an increase in sRAGE.

**Methods****Participants and Characteristics**

This secondary analysis uses data and blood collected from 3 previously published PA studies: an improving exercise

tolerance and health-related quality of life in Veterans with COPD study known as SAMO,<sup>40</sup> the Every Step Counts study (ESC),<sup>35</sup> and the Walking and Education to Breathe study (WEB).<sup>34</sup> SAMO was an observational study of daily step counts that enrolled participants with stable COPD from January 2009 to February 2011.<sup>40</sup> ESC and WEB were randomized controlled trials examining the efficacy of a web-based, pedometer-mediated intervention to increase PA compared to pedometer alone or a control group, respectively.<sup>34,35</sup> Participants were enrolled in ESC<sup>35</sup> from April 2012 to August 2015. They were randomized to 1 of 2 groups for 3 months: Omron HJ-720 ITC pedometer and a web-based PA intervention or Omron alone with written materials about exercise (i.e., control).<sup>35</sup> Participants were enrolled in WEB from May 2015 to February 2019 from 2 Veterans Affairs (VA) Medical Centers<sup>34</sup>; the current analyses use data from only one VA Medical Center. WEB participants were randomly assigned to either a Fitbit Zip pedometer and the same web-based PA intervention or usual care and written instructions for walking and exercise (i.e., control) for 6 months.<sup>34</sup> For all 3 studies, data from assessments and blood draws conducted at baseline and 3 months were used in this secondary analysis. Detailed information about these 3 studies is published elsewhere.<sup>34,35,40</sup>

In all 3 studies, at baseline, forced expiratory volume in 1 second (FEV<sub>1</sub>) was measured using an Eaglet spirometer (nSpire Health, Inc, Longmont, Colorado).<sup>41</sup> Body mass index (BMI) was calculated after measuring participants' height and weight. Using self-report and medical chart review, we ascertained age, sex, race, pack years, current supplemental oxygen use, history of coronary artery disease (CAD), history of congestive heart failure (CHF), and occurrence of AEs in the year prior to study entry.

### Systemic Biomarkers

At the baseline and 3-month visits, peripheral blood was collected by venipuncture into vacutainer tubes with ethylenediaminetetraacetic acid anticoagulant. Blood was collected between 9:00 AM and 4:00 PM. Plasma was obtained by centrifugation at 1459xg for 15 min. The samples were stored at -80 degrees Celsius in liquid nitrogen from the time they were drawn in the parent studies until the assays were performed in July 2021. There were no repeated freeze-thaw cycles. Plasma NT-proBNP, sRAGE, and CKMM levels were measured by the Clinical and Epidemiologic Research Laboratory, Children's Hospital, Boston, Massachusetts. NT-proBNP levels were determined using an electrochemiluminescent quantitative sandwich enzyme immunoassay technique on the Roche Cobas 6000 system (Roche Diagnostics, Indianapolis, Indiana). This immunoassay technique has a sensitivity of 5pg/mL and day-to-day imprecision values at concentrations of 46, 125, and 32,805pg/mL of 3.1%, 2.7%, and 2.7%, respectively.

sRAGE levels were determined using an enzyme-linked immunosorbent assay (ELISA) (R & D Systems, Minneapolis, Minnesota), specifically an enzymatically amplified "2-step" sandwich-type immunoassay. This ELISA assay detected any form of soluble RAGE, including sRAGE, endogenous secretory RAGE, and matrix metalloproteinase-cleaved membrane-bound RAGE. This assay has a sensitivity of 4.12pg/mL, and day-to-day variabilities of the assay at concentrations of 519, 1449, and 2890pg/mL are 8.2%, 8.2%, and 6.6% respectively. Lastly, CKMM levels were determined using an ELISA assay (Novus Biologicals, Centennial, Colorado) that uses the Sandwich-ELISA principle. This ELISA assay has a sensitivity of 0.94ng/mL and day-to-day variabilities of the assay at concentrations of 257.1 and 500.8ng/mL are 11.6% and 10.8%, respectively.

### Physical Activity and Exercise Performance

In the 3 studies, PA was directly measured as daily step count at baseline and 3 months. In SAMO, daily step counts were captured using the Omron pedometer and monitored over 14 days at baseline and 3 months.<sup>40</sup> In ESC, participants also wore the Omron pedometer; daily step counts were monitored over 7 days at baseline and 3 months.<sup>35</sup> In WEB, participants used the Fitbit Zip pedometer; daily step counts were monitored over 10 days at baseline and over 14 days at 3 months.<sup>34</sup> The Omron pedometer and the Fitbit Zip pedometer, both worn on the waist, accurately measure daily step counts in people with COPD.<sup>42,43</sup> Exercise performance was assessed by the 6-minute walk test (6MWT) at baseline and 3 months. The 6MWT was performed following American Thoracic Society guidelines, except that a practice test was not performed.<sup>44</sup>

### Statistical Analysis

All analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, North Carolina). Univariate analyses examined baseline sample characteristics: *t*-tests and analyses of variances assessed the association of systemic biomarker levels with categorical variables. Pearson correlations examined associations between biomarker levels and continuous variables. For the models examining whether the PA intervention impacted systemic biomarker levels, we maintained the randomization group assignments. Since no SAMO participants received the web-based PA intervention, they were considered controls. General linear models (PROC GLM) explored associations between: (1) baseline daily step count and 6MWT distance and baseline level of each systemic biomarker (NT-proBNP, sRAGE and CKMM), and (2) the effect of the PA intervention on change in systemic biomarkers, compared to controls.

Since systemic biomarker distributions were skewed, each value was natural log-transformed to meet model



assumptions. Change from baseline to 3 months for all biomarkers was calculated after the natural log-transformation, i.e.,  $\ln(3 \text{ months}) - \ln(\text{baseline})$ . For ease of interpretation of results, we calculated the concentration levels of each systemic biomarker by exponentiating the natural log-transformed estimates using a base of  $e$ . Clinical and demographic characteristics that were significantly associated with baseline levels of biomarkers were included as covariates. CAD and CHF were included in the main models because they are not necessarily interchangeable and CHF is an essential comorbidity when studying NT-proBNP. Final models adjusted for study, age, race, sex, FEV<sub>1</sub> percentage predicted (% pred), BMI, CAD, CHF, oxygen use, and history of AEs in the year prior to study entry. Statistical significance was defined as  $p < 0.05$ .

## Results

### Participant Characteristics

Of the 375 participants enrolled in the 3 studies, 366 had valid step-count data, performed the 6MWT, and provided blood samples at baseline. Most participants were White (93%,  $n=341$ ) and males (98%,  $n=357$ ) with mean age  $70 \pm 8$  years (Table 1). The mean daily step count was  $3141 \pm 2352$  and mean 6MWT distance was  $375 \pm 97$ m. Median NT-proBNP serum level was 132.80pg/ml (interquartile range [IQR]=60.93–383.80), median sRAGE serum level was 1017.48pg/ml (IQR=720.20–1402.65), and median CKMM serum level was 513.71ng/ml (IQR=399.71–676.06).

Higher Global initiative for chronic Obstructive Lung Disease (GOLD)<sup>45</sup> stage (i.e., lower FEV<sub>1</sub>%pred) was significantly associated with lower sRAGE, but not NT-proBNP or CKMM. Increased BMI was significantly associated with higher average CKMM (Supplemental Table E1 in the online supplement). Cigarette smoking history measured by pack years was not associated with systemic biomarker levels (Supplemental Table E2 in the online supplement). Participants with a history of CAD had higher mean levels of NT-proBNP and sRAGE compared to those without CAD. Participants with a history of CHF had higher mean levels of all 3 biomarkers, compared to those without CHF. Those using supplemental oxygen had higher mean NT-proBNP and CKMM levels than those not on oxygen. There was no difference in the 3 systemic biomarkers among those with at least one AE compared to those with no AE in the year prior to study entry. Compared to participants in SAMO, those in ESC and WEB had significantly lower levels of NT-proBNP. Finally, there was no difference in systemic biomarker levels between those in the intervention versus control groups (Supplemental Table E1 in the online supplement).

### Baseline Relationships

At baseline, adjusted models showed an association between higher daily step counts and lower NT-proBNP levels ( $\beta = -0.95$ pg/ml per 1000 steps per day, 95% confidence interval [CI] [-0.91, 1.00],  $p = .060$ ; Table 2). Baseline daily step counts were not associated with sRAGE (Supplemental Table E3 in the online supplement) or CKMM levels (Supplemental Table E4 in the online supplement). There was a significant association between higher 6MWT distance and lower NT-proBNP levels ( $\beta = -0.80$ pg/ml per 100 meters, 95% CI [-0.71, -0.92],  $p = .001$ ) (Table 3). Baseline 6MWT distance was not significantly associated with sRAGE (Supplemental Table E5 in the online supplement) or CKMM (Supplemental Table E6 in the online supplement) levels.

Compared to participants in SAMO, those in the ESC study had significantly higher levels of sRAGE and those in the WEB study had significantly lower levels of CKMM. Age was consistently an independent predictor of NT-proBNP, sRAGE, and CKMM levels, such that the greater the age, the higher the systemic biomarker levels. Lower FEV<sub>1</sub>%pred was significantly associated with lower sRAGE levels. Compared to those with normal BMI, those who were underweight had significantly lower CKMM levels, while those who were overweight or obese had significantly higher levels of CKMM. Compared to those with no history of CAD, participants with CAD had NT-proBNP concentrations that were 1.27 ( $p = .068$ ) to 1.30 ( $p = .051$ ) pg/ml higher. Finally, compared to those with no history of CHF, participants with CHF had NT-proBNP concentrations that were 2.62 to 2.80pg/ml higher ( $p \leq .001$ ).

### Effect of the PA Intervention

By randomization group, the mean 3-month change in daily step counts, adjusted for covariates, was significantly greater in the intervention group ( $789 \pm 1864$ ) compared to the control group ( $-174 \pm 1448$ ;  $\beta = 801.61$ , 95% CI [295, 1308],  $p = .002$ ; Figure 1, top panel). There was no significant difference in mean 3-month change in 6MWT distance between the intervention group and control group ( $2.14 \pm 157.91$ m versus  $0.37 \pm 146.81$ m,  $\beta = 1.75$ , 95% CI [-43.43, 46.92],  $p = .939$ ; Figure 1, bottom panel). There was no significant effect of randomization group on change in levels of NT-proBNP, sRAGE, or CKMM, compared to the control group (Figure 2).

## Discussion

In this secondary, exploratory data analysis, we show that at baseline, cross-sectionally higher exercise performance is statistically associated with lower NT-proBNP levels; there was no relationship between PA and exercise performance with sRAGE and CKMM. Additionally, we believe that for

**Table 1. Baseline Characteristics**

	Mean/n	Overall (N=30)
<b>Age (years)</b>	70	8
<b>Gender</b>		
Male	357	98%
Female	9	2%
<b>Race</b>		
White	341	93%
Other	25	7%
<b>FEV<sub>1</sub>%Pred</b>	59	21
<b>Pack Years</b>	62	38
<b>BMI Categories</b>		
Extremely Obese (>40kg/m <sup>2</sup> )	24	7%
Obese (30 to <40kg/m <sup>2</sup> )	122	33%
Overweight (25 to <30kg/m <sup>2</sup> )	134	37%
Normal (18.5 to <25kg/m <sup>2</sup> )	80	22%
Underweight (<18.5kg/m <sup>2</sup> )	6	2%
<b>Intervention Exposure</b>		
Control	258	70%
Intervention	108	30%
<b>Study</b>		
ESC	104	28%
WEB	100	27%
SAMO	162	44%
<b>Coronary Artery Disease</b>	93	25%
<b>Congestive Heart Failure</b>	38	10%
<b>Oxygen Use</b>	81	22%
<b>≥1 Acute Exacerbation</b>	76	21%
<b>6MWT Distance (m)</b>	375	97
<b>Daily Step Counts</b>	3141	2352
<b>NT-proBNP<sup>a</sup> (pg/ml)</b>	132.80	60.93–383.80
<b>sRAGE<sup>a</sup> (pg/ml)</b>	1017.48	720.20–1402.65
<b>CKMM<sup>a</sup> (ng/ml)</b>	513.71	399.71–676.06

(N=366)

<sup>a</sup>Represents median and interquartile range.

SD=standard deviation; FEV<sub>1</sub>%pred=forced expiratory volume in 1 second percentage predicted; BMI=body mass index; ESC=Every Step Counts study; WEB=Walking and Education to Breathe study; SAMO=improving exercise tolerance and health-related quality of life in Veterans with COPD study; 6MWT=6-minute walk test; NT-proBNP=N-terminal pro-β-type natriuretic peptide; sRAGE=soluble receptor for advanced glycation end products; CKMM=muscle type creatine kinase

the first time, we show that a 3-month PA intervention promoting community-based walking has no negative impacts on myocardial stress or muscle injury as assessed by NT-proBNP and CKMM, respectively. Physical activity promotion over 3 months also has no effect on systemic inflammation measured by sRAGE. Our preliminary findings suggest that PA promotion in the form of community-based walking over 3 months (as opposed to bouts of high-intensity exercise training in the laboratory) does not impact biomarker levels that would suggest cardiac dysfunction, skeletal muscle damage, or inflammation. These results may guide the personalization of PA interventions by helping to identify who can tolerate increases in exercise intensity and duration (if no change in blood biomarkers) and who requires decreases in intensity (if increase in blood biomarkers).

History of CAD and CHF were independent predictors of higher NT-proBNP levels in this cohort of participants with COPD, similar to that shown in the general population.<sup>46</sup> We showed that higher exercise performance in persons with COPD is significantly associated with lower NT-proBNP levels, likely reflecting a complex interaction between COPD disease severity and cardiovascular comorbidities such as CAD.<sup>3</sup> Secretion of NT-proBNP increases as myocardial wall stress increases and is a systemic biomarker for heart failure.<sup>47</sup> It is plausible that PA or exercise in persons with COPD is associated with dynamic hyperinflation or elevated pulmonary arterial pressure that may negatively impact cardiac function, with accompanying higher NT-proBNP levels.<sup>47-49</sup> However, we showed no negative impact of our 3-month PA intervention on myocardial stress and no relationship between change in daily step count or change

For personal use only. Permission required for all other uses.

**Table 2. General Linear Models Between Baseline Daily Step Counts and Baseline N-Terminal Pro-B-Type Natriuretic Peptide Levels<sup>a</sup>**

	ln(NT-proBNP)		NT-proBNP		p-value
	Estimate	SE	Estimate	SE	
<b>Daily Step Counts (1000)</b>	-0.05	0.03	-0.95	1.03	.060
<b>Study (ref=SAMO)</b>					
ESC	-0.19	0.14	-0.82	1.15	.156
WEB	0.09	0.16	1.09	1.18	.591
<b>Age</b>	0.08	0.01	1.08	1.01	<.001
<b>Race (ref=White)</b>					
Other	-0.02	0.22	-0.98	1.24	.914
<b>Sex (ref=Male)</b>					
Female	-0.11	0.36	-0.90	1.43	.767
<b>FEV<sub>1</sub>%pred</b>	-1.18E-03	2.78E-03	-1.00	1.00	.671
<b>BMI (ref=Normal)</b>					
Extremely Obese	-0.24	0.24	-0.79	1.28	.323
Obese	-0.10	0.15	-0.90	1.16	.490
Overweight	-0.16	0.15	-0.85	1.16	.285
Underweight	0.51	0.42	1.67	1.53	.225
<b>CAD (ref=No)</b>					
Yes	0.26	0.13	1.30	1.14	.051
<b>CHF (ref=No)</b>					
Yes	1.03	0.19	2.80	1.21	<.001
<b>Oxygen Use (ref=No)</b>					
Yes	0.08	0.14	1.08	1.15	.569
<b>Acute Exacerbation (ref=None)</b>					
≥1 Event	0.12	0.16	1.13	1.17	.450

<sup>a</sup>pg/mL

NT-proBNP=N-terminal pro-B-type natriuretic peptide; SE=standard error; SAMO= improving exercise tolerance and health-related quality of life in Veterans with COPD study; ESC=Every Step Counts study; WEB=Walking and Education to Breathe study; FEV<sub>1</sub>%pred=forced expiratory volume in 1 second percentage predicted; BMI=body mass index; CAD=coronary artery disease; CHF=congestive heart failure

in 6MWT distance with change in NT-proBNP. These results suggest that the magnitude of changes in daily step count and 6MWT distance observed over 3 months, which spanned a wide range, do not negatively impact cardiac function.

More recently, there has been interest in sRAGE which has emerged as an inflammatory biomarker common across several clusters in COPD.<sup>26</sup> We showed that there is no significant association between daily step counts or 6MWT distance and sRAGE. We also showed that lower FEV<sub>1</sub>%pred (i.e., greater COPD disease severity) is significantly associated with lower sRAGE (i.e., greater systemic inflammation) which is consistent with published findings.<sup>23,24</sup> Although exercise training, pulmonary rehabilitation, and PA promotion have demonstrated benefits in COPD, an anti-inflammatory effect of exercise has not yet been established.<sup>16-22</sup> Most COPD studies, heterogeneous with respect to intensity, duration, frequency, and type of exercise studied, have focused on only 1 or a limited number of biomarkers of systemic inflammation.<sup>16-22</sup> We have previously shown cross-sectionally that greater PA as measured by daily step counts is associated with lower plasma levels of C-reactive protein and interleukin-6, two inflammatory biomarkers in COPD.<sup>50,51</sup>

There is conflicting literature on the impact of exercise training on biomarkers of systemic inflammation. The current results do not show an impact of our web-based, pedometer-mediated promotion of community-based walking specifically on sRAGE. It is plausible that more strenuous exercise is needed to impact expression of sRAGE. In addition, 3 months may have been insufficient time to effect changes on sRAGE levels. There is one published study<sup>52</sup> examining community-based PA in persons with COPD as promoted with a cell phone intervention that showed decreases in serum C-reactive protein and interleukin-8. In the general population, a few studies have shown conflicting results in terms of the effects of exercise training and PA promotion on sRAGE.<sup>53-55</sup> Army recruits engaged in a 4-week exercise intervention had decreases in sRAGE<sup>53</sup> and community volunteers in Japan enrolled in a 6-month PA promotion program had decreases in sRAGE,<sup>54</sup> while a study of adults aged 30–65 with at least one cardiovascular risk factor engaged in an 8-month PA program had an increase in sRAGE.<sup>55</sup>

Finally, decreased PA in persons with COPD and the resultant progressive muscle deconditioning may lead to disuse atrophy.<sup>4</sup> A common symptom of COPD is "muscle

For personal use only. Permission required for all other uses.

**Table 3. General Linear Models Between Baseline 6-Minute Walk Test Distance and Baseline N-Terminal Pro-B-Type Natriuretic Peptide Levels<sup>a</sup>**

Parameter	ln(NT-proBNP)		NT-proBNP		p-value
	Estimate	SE	Estimate	SE	
<b>6MWT Distance (1000)</b>	-0.22	0.07	-0.80	1.07	.001
<b>Study (ref=SAMO)</b>					
ESC	-0.21	0.13	-0.81	1.14	.126
WEB	0.08	0.16	1.08	1.17	.633
<b>Age</b>	0.07	0.01	1.07	1.01	<.001
<b>Race (ref=White)</b>					
Other	-0.06	0.22	-0.94	1.24	.772
<b>Sex (ref=Male)</b>					
Female	-0.25	0.36	-0.78	1.43	.490
<b>FEV<sub>1</sub>%pred</b>	0.00	0.00	-1.00	1.00	.920
<b>BMI (ref=Normal)</b>					
Extremely Obese	-0.24	0.24	-0.79	1.27	.321
Obese	-0.13	0.15	-0.88	1.16	.381
Overweight	-0.16	0.14	-0.85	1.16	.263
Underweight	0.48	0.42	1.61	1.52	.254
<b>CAD (ref=No)</b>					
Yes	0.24	0.13	1.27	1.14	.068
<b>CHF (ref=No)</b>					
Yes	0.96	0.19	2.62	1.21	<.001
<b>Oxygen Use (ref=No)</b>					
Yes	0.01	0.14	1.01	1.15	.965
<b>Acute Exacerbation (ref=None)</b>					
≥1 Event	0.09	0.16	1.10	1.17	.561

<sup>a</sup>pg/mL

NT-proBNP=N-terminal pro-B-type natriuretic peptide; SE=standard error; 6MWT=6-minute walk test; SAMO=improving exercise tolerance and health-related quality of life in Veterans with COPD study; ESC=Every Step Counts study; WEB=Walking and Education to Breathe study; FEV<sub>1</sub>%pred=forced expiratory volume in 1 second percentage predicted; BMI=body mass index; CAD=coronary artery disease; CHF=congestive heart failure

wasting," in which several factors, including disuse and hypoxemia, lead to muscle atrophy.<sup>49</sup> We showed no significant cross-sectional associations between PA and exercise performance with CKMM. Since previous studies have examined short, exhaustive exercise training in the laboratory, it is unclear what effects longer-term PA promotion to counter deconditioning may have on skeletal muscles and CKMM levels. We demonstrated no changes in CKMM in response to our PA intervention. Our results suggest that community-based walking in persons with COPD over a 3-month timeframe, resulting in the magnitude of change in daily step count and 6MWT distance we observed, does not damage skeletal muscles as reflected in the lack of change in CKMM levels. Previous small studies of short, exhaustive exercise training in the laboratory in persons with COPD have demonstrated mixed results with increased serum levels of creatine kinase, including CKMM, while others have shown no change in CK levels.<sup>27-31</sup> Interestingly, BMI is an independent predictor of CKMM, with those who are overweight or obese having higher CKMM levels and those who are underweight having lower CKMM levels, compared to those with a normal BMI.


It is possible that we observed no changes in the

biomarkers because the intensity and duration of our intervention were not sufficient to elicit changes. We see it as a good thing that there is no biomarker evidence for myocardial stress or muscle injury after a 3-month community-based walking PA intervention that has been shown to result in increases in daily step counts which are statistically and clinically significant. In the parent randomized clinical trials (RCTs), the PA intervention has been shown to be efficacious in improving daily step counts by 779–1312 steps per day, compared to controls.<sup>33-35</sup> These improvements are both clinically and statistically significant based on published minimal clinically important differences for daily step count.<sup>37,38</sup> Importantly, we showed that this modest increase in daily step counts in this frail population is associated with a reduction in risk for acute exacerbations.<sup>39</sup> For these clinically significant and statistically significant observed changes in physical activity, we did not see any changes in the biomarkers. Our goal was not to develop an intervention of such intensity or duration that there would be deleterious impacts on the heart and skeletal muscles to see increases in NT-proBNP and CKMM.

While participants in the intervention groups in ESC and WEB, on average, improved their daily step count more

For personal use only. Permission required for all other uses.



**Figure 1. Distribution of 3-Month Change in Daily Step Count and 6-Minute Walk Test**

(6MWT) Distance by Group Assignment. Values adjusted for study, age, race, sex, FEV<sub>1</sub>%pred, BMI, CAD, CHF, oxygen use, and history of AEs in the year prior to study entry. Y-axis Percent reflects the percentage within each randomization group (Daily Step Count: Control n=170, Intervention n=96; 6MWT distance: Control n=177, Intervention n=99).

6MWT=6-minute walk test; FEV<sub>1</sub>%pred=forced expiratory volume in 1 second percentage predicted; BMI=body mass index; CAD=coronary artery disease; CHF=congestive heart failure; AEs=acute exacerbations

than the control groups, there were participants in both randomization groups who experienced improvements from baseline. In analyses combining the groups and examining baseline and 3-month change values of daily step count and 6MWT distance and levels of systemic biomarkers, independent of group assignment, the results were similar to what we report. In our cross-sectional analyses, we presented the model estimates per 1000 steps per day and per 100 meters for the 6MWT to view the numbers most easily. However, the clinical implications of these estimates remain unclear as these results are cross-sectional associations, precluding any conclusions about causal changes in NT-proBNP.


This secondary data analysis has many strengths including the well-characterized cohort of participants with COPD, a PA intervention with proven efficacy, and the ability to examine change in PA/exercise performance and change in systemic biomarker levels across 3 months in a large sample. The biomarkers examined represent a broad spectrum of systemic responses to PA and exercise. Our novel finding that a PA intervention promoting community-based walking has no deleterious effects on myocardial

stress, systemic inflammation, and muscle injury assessed by NT-proBNP, sRAGE, and CKMM, respectively, is useful in guiding clinical care. Although we did not observe significant relationships between changes in PA/exercise performance and changes in systemic biomarker levels, these results are important to inform how best to monitor systemic response to PA promotion in COPD.

We were limited in the exploratory nature of this data analysis that combined 3 separate studies with significant differences in sRAGE and CKMM between studies. Nevertheless, all models adjusted for study to account for these differences. We acknowledge the missing follow-up data and that the results reflect only the subset of participants who participated in follow-up. The demographics of the populations from each study were homogeneous, with most participants being White, male, and U.S. Veterans, limiting the generalizability of these results to other populations. The follow-up time of 3 months was relatively short and may not have allowed enough time for changes in serum biomarker levels to occur. We acknowledge that it is unknown whether the biomarker levels assessed at 3 months reflect PA/exercise over the preceding 3 months or merely the preceding 3

For personal use only. Permission required for all other uses.



**Figure 2. Distribution of 3-Month Change in Systemic Biomarker Levels by Group Assignment**

Values adjusted for study, age, race, sex, FEV<sub>1</sub>%pred, BMI, CAD, CHF, oxygen use, and history of AEs in the year prior to study entry. Y-axis Percent reflects the percentage within each group. (Control n=174; Intervention n=98).

FEV<sub>1</sub>%pred=forced expiratory volume in 1 second percentage predicted; BMI=body mass index; CAD=coronary artery disease; CHF=congestive heart failure; AEs=acute exacerbations; NT-proBNP=N-terminal pro-B-type natriuretic peptide; sRAGE=soluble receptor for advanced glycation end products; CKMM=muscle type creatine kinase

hours or 3 days. However, it is certainly a different time point compared to the measurement collected at baseline since participants have been engaged in a 3-month PA intervention with ongoing community-based walking. There is very limited literature examining the long-term stability of these biomarkers. However, there is precedence for analysis of samples that have undergone long-term storage. For example, 3 NHANES studies<sup>56-58</sup> published in 2023 examined NT-proBNP in samples collected between 1999–2004 while the assays were performed 19–21 years later between 2018–2020. We emphasize that

we are not presenting absolute values as thresholds for clinical decision-making. If there is decay, the decline in values would affect both groups with no preferential bias for one group over another. The cohort included only 4 current smokers precluding any informative subgroup analyses on smoking status. Although the parent RCTs would have balanced unmeasured confounders between groups, it is possible that variables such as chronic kidney disease and diuretic use may impact the results of our models. These relationships should be further explored in future studies, tracking systemic biomarker levels over longer

For personal use only. Permission required for all other uses.

periods of time with interventions of varying levels of exercise intensity to better understand systemic responses to PA promotion in persons with COPD.

## Conclusions

Higher 6MWT distance is associated with lower NT-proBNP levels. A 3-month PA intervention promoting community-based walking has no negative impacts on myocardial stress or muscle injury as assessed by NT-proBNP and CKMM, respectively. It also has no effect on systemic inflammation measured by sRAGE. These results may help personalize PA interventions and identify who can tolerate increases in exercise intensity and duration. Further studies are needed

to understand the systemic biomarker responses to PA and exercise promotion in persons with COPD.

## Acknowledgments

**Author contributions:** All authors contributed to the conception of the work, the analysis and interpretation of data for the work, drafting and revising the work critically for important intellectual content, and final approval of the version submitted for publication.

## Declaration of Interest

The authors have no conflicts of interest to declare.

## References

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. *Am J Respir Crit Care Med.* 2017;195(5):557-582. <https://doi.org/10.1164/rccm.201701-0218PP>
2. Choudhury G, Rabinovich R, MacNee W. Comorbidities and systemic effects of chronic obstructive pulmonary disease. *Clin Chest Med.* 2014;35(1):101-130. <https://doi.org/10.1016/j.ccm.2013.10.007>
3. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? *Eur Respir Rev.* 2018;27:180057. <https://doi.org/10.1183/16000617.0057-2018>
4. Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2014;189(9):e15-e62. <https://doi.org/10.1164/rccm.201402-0373ST>
5. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. *Thorax.* 2006;61(9):772-778. <https://doi.org/10.1136/thx.2006.060145>
6. Moy ML, Gould MK, Liu I-LA, Lee JS, Nguyen HQ. Physical activity assessed in routine care predicts mortality after a COPD hospitalisation. *ERJ Open Res.* 2016;2(1). <https://doi.org/10.1183/23120541.00062-2015>
7. Moy ML, Teylan M, Weston NA, Gagnon DR, Garshick E. Daily step count predicts acute exacerbations in a US cohort with COPD. *PLoS One.* 2013;8(4):e60400. <https://doi.org/10.1371/journal.pone.0060400>
8. Nguyen HQ, Chu L, Amy Liu I-L, et al. Associations between physical activity and 30-day readmission risk in chronic obstructive pulmonary disease. *Ann Am Thorac Soc.* 2014;11(5):695-705. <https://doi.org/10.1513/AnnalsATS.201401-017OC>
9. Vaes AW, Garcia-Aymerich J, Marott J L, et al. Changes in physical activity and all-cause mortality in COPD. *Eur Respir J.* 2014;44(5):1199-1209. <https://doi.org/10.1183/09031936.00023214>
10. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. *Chest.* 2011;140(2):331-342. <https://doi.org/10.1378/chest.10-2521>
11. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. *Am J Respir Crit Care Med.* 2008;177(7):743-751. <https://doi.org/10.1164/rccm.200707-1011OC>
12. Labaki WW, Xia M, Murray S, et al. NT-proBNP in stable COPD and future exacerbation risk: analysis of the SPIROMICS cohort. *Respir Med.* 2018;140:87-93. <https://doi.org/10.1016/j.rmed.2018.06.005>
13. Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. *Chron Respir Dis.* 2017;14(2):117-126. <https://doi.org/10.1177/1479972316674393>
14. Hawkins NM, Khosla A, Virani SA, McMurray JJV, FitzGerald JM. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. *BMC Pulm Med.* 2017;17:11. <https://doi.org/10.1186/s12890-016-0345-7>
15. Chi SY, Kim EY, Ban HJ, et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. *Lung.* 2012;190:271-276. <https://doi.org/10.1007/s00408-011-9363-7>
16. Bolton CE, Broekhuizen R, Ionescu AA, et al. Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD. *Thorax.* 2007;62(2):109-114. <https://doi.org/10.1136/thx.2006.060368>
17. Thyregod M, Løkke A, Skou ST, Larsen J, Bodtger U. Changes in systemic inflammation after pulmonary rehabilitation in patients with COPD and severe physical inactivity—an exploratory study. *Chron Respir Dis.* 2022;19. <https://doi.org/10.1177/14799731221112439>
18. Sanches Pereira do Nascimento E, Maria Sampaio Malosa L, Peixoto-Souza FS, et al. Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients. *Int J Chron Obstruct Pulmon Dis.* 2015;10(1):645-653. <https://doi.org/10.2147/COPD.S76216>
19. Jenkins AR, Holden NS, Jones AW. Inflammatory responses to acute exercise during pulmonary rehabilitation in patients with COPD. *Eur J Appl Physiol.* 2020;120:2301-2309. <https://doi.org/10.1007/s00421-020-04452-z>
20. Spruit MA, Gosselink R, Troosters T, Kasran A, Van Vliet M, Decramer M. Low-grade systemic inflammation and the response to exercise training in patients with advanced COPD. *Chest.* 2005;128(5):3183-3190. <https://doi.org/10.1378/chest.128.5.3183>
21. Van Der Vlist J, Janssen TW. The potential anti-inflammatory effect of exercise in chronic obstructive pulmonary disease. *Respiration.* 2010;79(2):160-174. <https://doi.org/10.1159/000233264>
22. Neunhäuserer D, Patti A, Niederseer D, et al. Systemic inflammation, vascular function, and endothelial progenitor cells after an exercise training intervention in COPD. *Am J Med.* 2021;134(3):e171-e180. <https://doi.org/10.1016/j.amjmed.2020.07.004>
23. Sharma A, Kaur S, Sarkar M, Sarin BC, Changotra H. The AGE-RAGE axis and RAGE genetics in chronic obstructive pulmonary disease. *Clin Rev Allergy Immunol.* 2021;60:244-258. <https://doi.org/10.1007/s12016-020-08815-4>
24. Yonchuk JG, Silverman EK, Bowler RP, et al. Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung. *Am J Respir Crit Care Med.* 2015;192(7):785-792. <https://doi.org/10.1164/rccm.201501-0137PP>

25. Serban KA, Pratte KA, Bowler RP. Protein biomarkers for COPD outcomes. *Chest*. 2021;159(6):2244-2253. <https://doi.org/10.1016/j.chest.2021.01.004>
26. Vanfleteren LEGW, Weidner J, Franssen FME, et al. Biomarker-based clustering of patients with chronic obstructive pulmonary disease. *ERJ Open Res*. 2023;9. <https://doi.org/10.1183/23120541.00301-2022>
27. Brancaccio P, Maffulli N, Limongelli FM. Creatine kinase monitoring in sport medicine. *Br Med Bull*. 2007;81-82(1):209-230. <https://doi.org/10.1093/bmb/ldm014>
28. van Helvoort HAC, van de Pol MHJ, Heijdra YF, Dekhuijzen PNR. Systemic inflammatory response to exhaustive exercise in patients with chronic obstructive pulmonary disease. *Respir Med*. 2005;99(12):1555-1567. <https://doi.org/10.1016/j.rmed.2005.03.028>
29. Silva BSA, Ramos D, Camillo CA, et al. Resistance training with elastic tubing improves muscle strength, exercise capacity, and post-exercise creatine kinase clearance in subjects with COPD. *Respir Care*. 2019;64(7):835-843. <https://doi.org/10.4187/respcare.05975>
30. Mujaddadi A, Moiz JA, Singla D, Naqvi IH, Ali MS, Talwar D. Effect of eccentric exercise on markers of muscle damage in patients with chronic obstructive pulmonary disease. *Physiother Theory Pract*. 2021;37(7):801-807. <https://doi.org/10.1080/09593985.2019.1644690>
31. Camillo CA, Burtin C, Hornikx M, et al. Physiological responses during downhill walking: a new exercise modality for subjects with chronic obstructive pulmonary disease? *Chron Respir Dis*. 2015;12(2):155-164. <https://doi.org/10.1177/1479972315575717>
32. Martinez CH, Moy ML, Nguyen HQ, et al. Taking healthy steps: rationale, design and baseline characteristics of a randomized trial of a pedometer-based internet-mediated walking program in veterans with chronic obstructive pulmonary disease. *BMC Pulm Med*. 2014;14:12. <https://doi.org/10.1186/1471-2466-14-12>
33. Moy ML, Collins RJ, Martinez CH, et al. An internet-mediated pedometer-based program improves health-related quality-of-life domains and daily step counts in COPD. *Chest*. 2015;148(1):128-137. <https://doi.org/10.1378/chest.14-1466>
34. Robinson SA, Cooper JA, Goldstein RL, et al. A randomised trial of a web-based physical activity self-management intervention in COPD. *ERJ Open Res*. 2021;7. <https://doi.org/10.1183/23120541.00158-2021>
35. Wan ES, Kantorowski A, Homsy D, et al. Promoting physical activity in COPD: insights from a randomized trial of a web-based intervention and pedometer use. *Respir Med*. 2017;130:102-110. <https://doi.org/10.1016/j.rmed.2017.07.057>
36. Boekaerts M, Zeidner M, eds. *Handbook of Self-Regulation*. Academic Press; 2000.
37. Demeyer H, Burtin C, Hornikx M, et al. The minimal important difference in physical activity in patients with COPD. *PLoS One*. 2016;11(4):e0154587. <https://doi.org/10.1371/journal.pone.0154587>
38. Teylan M, Kantorowski A, Homsy D, Kadri R, Richardson C, Moy ML. Physical activity in COPD: minimal clinically important difference for medical events. *Chron Respir Dis*. 2019;16. <https://doi.org/10.1177/1479973118816424>
39. Wan ES, Kantorowski A, Polak M, et al. Long-term effects of web-based pedometer-mediated intervention on COPD exacerbations. *Respir Med*. 2020;162:105878. <https://doi.org/10.1016/j.rmed.2020.105878>
40. Moy ML, Danilack VA, Weston NA, Garshick E. Daily step counts in a US cohort with COPD. *Respir Med*. 2012;106(7):962-969. <https://doi.org/10.1016/j.rmed.2012.03.016>
41. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. *Am J Respir Crit Care Med*. 2019;200(8):e70-e88. <https://doi.org/10.1164/rccm.201908-1590ST>
42. Moy ML, Janney AW, Nguyen HQ, et al. Use of pedometer and Internet-mediated walking program in patients with chronic obstructive pulmonary disease. *J Rehabil Res Dev*. 2010;47(5):485-496. <https://doi.org/10.1682/JRRD.2009.07.0091>
43. Prieto-Centurion V, Bracken N, Norwick L, et al. Can commercially available pedometers be used for physical activity monitoring in patients with COPD following exacerbations? *Chronic Obstr Pulm Dis*. 2016;3(3):636-642. <https://doi.org/10.15326/jcopdf.3.3.2015.0164>
44. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166:111-117. <https://doi.org/10.1164/ajrccm.166.1.at1102>
45. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD, 2019 report. GOLD website. Published 2019. Accessed October 2023. <https://www.goldcopd.org>.
46. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. *N Engl J Med*. 2005;352(7):666-675. <https://doi.org/10.1056/NEJMoa042330>
47. Santoso A, Maulana R, Alzahra F, et al. The effects of aerobic exercise on N-terminal pro-B-type natriuretic peptide and cardiopulmonary function in patients with heart failure: a meta-analysis of randomised clinical trials. *Heart Lung Circ*. 2020;29(12):1790-1798. <https://doi.org/10.1016/j.hlc.2020.05.098>
48. Wang H-Y, Xu Q-F, Xiao Y, Zhang J, Sperry A. Cardiac response and N-terminal-pro-brain natriuretic peptide kinetics during exercise in patients with COPD. *Respir Care*. 2011;56(6):796-799. <https://doi.org/10.4187/respcare.00935>
49. Shafuddin E, Chang CL, Cooray M, et al. Changes in biomarkers of cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. *Respir Med*. 2018;145:192-199. <https://doi.org/10.1016/j.rmed.2018.11.008>



- 
50. Moy ML, Teylan M, Danilack VA, Gagnon DR, Garshick E. An index of daily step count and systemic inflammation predicts clinical outcomes in chronic obstructive pulmonary disease. *Ann Am Thorac Soc*. 2014;11(2):149-157. <https://doi.org/10.1513/AnnalsATS.201307-243OC>
- 
51. Moy ML, Teylan M, Weston NA, Gagnon DR, Danilack VA, Garshick E. Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD. *Chest*. 2014;145(3):542-550. <https://doi.org/10.1378/chest.13-1052>
- 
52. Wang C-H, Chou P-C, Joa W-C, et al. Mobile-phone-based home exercise training program decreases systemic inflammation in COPD: a pilot study. *BMC Pulm Med*. 2014;14:142. <https://doi.org/10.1186/1471-2466-14-142>
- 
53. Drosatos I-A, Tsoporis JN, Izhar S, et al. Differential regulation of circulating soluble receptor for advanced glycation end products (sRAGEs) and its ligands S100A8/A9 four weeks post an exercise intervention in a cohort of young Army recruits. *Biomolecules*. 2021;11(9):1354. <https://doi.org/10.3390/biom11091354>
- 
54. Kotani K, Caccavello R, Sakane N, Yamada T, Taniguchi N, Gugliucci A. Influence of physical activity intervention on circulating soluble receptor for advanced glycation end products in elderly subjects. *J Clin Med Res*. 2011;3(5):252-257. <https://doi.org/10.4021/jocmr704w>
- 
55. Sponder M, Campean I-A, Emich M, et al. Long-term physical activity leads to a significant increase in serum sRAGE levels: a sign of decreased AGE-mediated inflammation due to physical activity? *Heart Vessels*. 2018;33:893-900. <https://doi.org/10.1007/s00380-018-1125-5>
- 
56. Commodore-Mensah Y, Wang D, Jeon Y, et al. Racial and ethnic differences in circulating N-terminal pro-brain-type natriuretic peptide (NT-proBNP) in US adults. *Am J Prev Cardiol*. 2023;15:100526. <https://doi.org/10.1016/j.ajpc.2023.100526>
- 
57. Ozkan B, Grams ME, Coresh J, et al. Associations of N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, and mortality in US adults. *Am Heart J*. 2023;264:49-58. <https://doi.org/10.1016/j.ahj.2023.05.014>
- 
58. Yang P, Rooney MR, Wallace AS, et al. Associations between diet quality and NT-proBNP in U.S. adults, NHANES 1999-2004. *Am J Prev Cardiol*. 2023;16:100528. <https://doi.org/10.1016/j.ajpc.2023.100528>
-